key: cord-0768474-0twsor36
authors: Bevilaqua, Mariele; Ribolli, Gustavo B.; Luzzatto, Laura; Fernandes, Juliana C.; Pasqualotto, Alessandro C.; Bonamigo, Renan R.
title: SDRIFE‐like rash in COVID‐19 patient: drug reaction or another cutaneous manifestation of SARS‐CoV‐2?
date: 2021-03-14
journal: Int J Dermatol
DOI: 10.1111/ijd.15537
sha: bd326ee042bc9862d1f7104b73d8b9cbe4d32d30
doc_id: 768474
cord_uid: 0twsor36

nan

exanthema (SDRIFE) is described as a benign and self-limiting type IV hypersensitivity due to a systemic drug that occurs in the absence of systemic involvement. 1, 2 It is hallmarked by a symmetric, well-demarcated erythema of the gluteal area and/or V-shaped erythema of the perigenital region, in addition to at least one other intertriginous area. 1, 2 A 71-year-old woman with asthma and hypothyroidism was admitted to the emergency unit with a high fever, prostration, myalgia, dry cough, coryza, and diarrhea after returning from a cruise off the Brazilian coast. Her breathing worsened, and a chest CT showed pneumonia with moderate ground-glass pattern. A RT-PCR test and immunochromatographic assay with IgM/IgG antibodies for SARS-CoV-2 were positive. She 

Symmetrical drug-related intertriginous and flexural exanthema: a little-known drug allergy

A new proposal for a clinical-oriented subclassification of baboon syndrome and a review of baboon syndrome

Litt's Drug Eruption & Reaction Manual 25E

Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Funding source: None. doi: 10.1111/ijd.15537